Home > About GAMMAGARD LIQUID > Side Effects

GAMMAGARD LIQUID IV Side Effects

Side effects may occur with IV Ig treatment, and they are more likely to occur when you are getting treatment for the first time or receiving a new product.1,2

The most common side effects* with IV infusions of GAMMAGARD LIQUID treatment, observed in ≥5% of the study subjects in the clinical trial, are shown below.

Most Common Side Effects2

  • headache
  • fatigue
  • fever
  • nausea
  • chills/shaking chills
  • pain in extremity
  • diarrhea
  • migraine
  • dizziness
  • vomiting
  • cough
  • hives
  • asthma
  • throat pain
  • rash
  • joint pain
  • muscle pain
  • swelling
  • itching
  • cardiac murmur

*Side effects are defined as events occurring during or within 72 hours of infusion or any causally related event occurring within the study period.2

You may experience some of these side effects after the infusion. If you experience any serious side effects such as blood clots, kidney problems, serious allergic reactions (hives, swelling in the mouth, or trouble breathing) or other serious symptoms, stop the infusion immediately and contact your healthcare professional or emergency services.2

It's important to talk to your healthcare provider about what to expect with intravenous administration of GAMMAGARD LIQUID treatment. Your doctor, nurse, or other healthcare professional can help you prepare for treatment and tell you what can be done to manage possible side effects. Also, resources and support are available to help you understand your treatment.

References: 1. Younger MEM, ed. IDF Guide for Nurses: Immunoglobulin Therapy for Primary Immunodeficiency Diseases. 4th ed. Towson, MD: Immune Deficiency Foundation; 2016. 2. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc.

    

  • Sign up to get access to experienced Patient and Nurse Advocates, insurance and financial support, useful tools, and more.
    Enroll Now
  • 
  • Ask an Advocate Questions about PI or PI treatments? Our trained Patient and Nurse Advocates can help, and asking your question is easy with our Ask An Advocate feature.
    Start Getting Answers

Gammagard Liquid MyIgCoPayCard Program Terms and Conditions

This manufacturer's coupon program is not valid for prescriptions reimbursed, in whole or in part, by Medicaid, Medicare, Medigap, VA, DoD, TRICARE, or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by the health insurance provider or by law

Shire's MyIgCoPayCard program provides a maximum total benefit of $5,000 for eligible out-of-pocket costs and expires 12 months from date of activation. Eligible costs include deductible, copayment, and co-insurance costs for eligible Shire IG (Immunoglobulin) products. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible.

To be eligible, patients must: 1. be starting or receiving treatment with (and have current prescription for) an eligible Shire IG product with an ICD-10 for a diagnosis of Primary Immunodeficiency; and 2. have commercial insurance that covers medication costs for prescribed Shire IG product and allows for CoPay assistance; and 3. be two (2) years old or older.

Acceptance of this offer must be consistent with the terms of benefits provided by patient's health insurance provider.

Offer limited to one card per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, or other offer.

This program is only valid for residents of the United States.

Shire reserves the right to change or discontinue this program at any time without notice.

This is not health insurance.

-----

Add to patient instructions:

If your insurance situation changes, it is your responsibility to notify MyIgSource's CoPay assistance program.


© 2017 Shire. All rights reserved.

SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. Gammagard Liquid is a trademark or registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

S30515 04/17

Please expand for Indication and Important Safety Information.

Selected Important Safety Information for GAMMAGARD LIQUID
  • GAMMAGARD LIQUID can cause decreased kidney function or kidney failure, blood clots in the heart, brain, lungs or elsewhere in the body. Call your healthcare professional or go to your emergency department right away if you have: Reduced urination, sudden weight gain, or swelling in your legs. These could be signs of a kidney problem. Pain, swelling, warmth, redness, or a lump in your legs or arms. These could be signs of a blood clot.
  • Do not take GAMMAGARD LIQUID if you have a known history of a severe allergic reaction to IgG or other blood products.